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Abstract 
The recent International Symposium on Molecular epidemiology in Embryonal Tumours and Paediatric Leukaemia was held on 4–6 
March 2008 in Rio de Janeiro, Brazil. It proved a very productive meeting in which studies relating to genetics, therapeutical trials, 
identification of risk factors in acute leukaemia neuroblastoma and Wilms’ tumours were presented. Over 120 participants gathered for 
three days of fruitful discussions, including representatives of paediatrics, haematology, laboratory, epidemiology and pathology. Debates 
were held about strategies of applications of important biomarkers for clinical trials. Highlights of each of the scientific presentations are 
summarized below. 
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Introduction 
The First Symposium on Molecular Epidemiology in Childhood 
Leukaemia was held in June 2006 to gather colleagues to 
discuss and work together on molecular epidemiology in 
childhood acute leukaemia. During this meeting, the preliminary 
results of the Brazilian Collaborative Study Group of Infant 
Acute Leukaemia (BCSGIAL) were discussed, and the 
commitment of several institutions was consolidated. Since then 
a centralized biological reservoir of material in INCA has 
allowed studies on environmental factors and biomarkers in 
childhood leukaemia to start. A second symposium was 
organized for the results of previous studies, and to start a new 
programme for the study of molecular epidemiology in 
paediatric embryonic tumours. The content of the programme 
predominantly includes acute leukaemia Wilms’ tumour (WT) 
and neuroblastoma. 
This second symposium was opened by Marisa Breitenbach, 
the coordinator of the Instituto Nacional do Câncer Rio de 
Janeiro. Paulo de Biase (Director INCA Rio de Janeiro) 
welcomed all the participants from abroad and from other parts 
of Brazil. He acknowledged the importance of international 
meetings for the exchange of knowledge in order to improve the 
understanding and treatment of childhood cancer. Marisa 
Breitenback emphasized the dedication of the participants of the 
Haematology-Oncology Paediatric Program carrying out 
multidisciplinary research as an exemplary approach to the 
challenges of cancer research. As the official spokeswoman for 
the institute, she discussed the development of the Instituto 
Nacional de Câncer in promoting the interaction between basic 
scientific researchers and members of the medical society, 
reinforcing the link between education, research and clinical 
innovations. Increased research funding and the establishment 
of advanced translational research infrastructures were also 
discussed. 
 
Acute leukaemia 
The two-hit model, as a paradigm explanation for the 
etiopathology of childhood common acute lymphoblastic 
leukaemia (c-ALL), was reviewed by Joseph Wiemels (UCLA-
San Francisco, USA). Sustained by the molecular 
epidemiological data, he demonstrated that specific gene 
fusions (TEL-AML1) occurring prenatally are important, but not 
exclusive markers for clinical phenotype. The biologic pathway 
of TEL-AML1 leukaemia was further discussed and candidates 
for the second post-natal hit were outlined. This second hit 
could be related to infectious disease, pesticide exposure and 
the deletion of p arm of chromosome 12. The biological 
evidence of Ras mutations occurring post-natally was also 
presented (from Guthrie card data). Loss of heterozygosity in a 
common region of chromosome 14 was also disclosed as an 
important factor in the scenario of ALL pathogenesis. In 
summary, the two-hit model for the development of c-ALL was 
proposed; the challenge is now to understand the role of 
delayed infections, exposure to pesticides and the impact of 
gene promoter methylation signature in its pathogenesis. 
Two studies, (1) the Northern California Childhood Leukaemia 
Study by Catherine Metayer (University of California, Berkeley, 
USA) and (2) from BCSGIAL by Sergio Koifman (Escola 
Nacional de Saúde Publica, Brazil), addressing parental 
exposure and environmental factors, were the subject of a 
roundtable discussion. 
The epidemiological studies conducted in Berkeley focused on 
exposure to home and agricultural pesticides, the timing of 
exposure and carcinogenesis. On the basis of the two-hit model 
hypothesis, the design of these studies analysed the 
questionnaires compiled by mothers of children with leukaemia, 
taking into account geographic distribution and biological 
markers. Preliminary data demonstrated that the use of paint at 
home during the post-natal period presented an OR of 1.37 
95%CI (1.05–1.79) for ALL in the offspring, whereas the risk of 
AML was OR 2.54 95%CI (1.19-5.42) for petroleum solvents. 
The data were analysed according to cytogenetic status. 
Although based on small numbers, the association found with 
paint and solvent exposures diverged markedly, depending on 
the abnormal karyotype, suggesting that a role for subtype-
specific pathways and genetic susceptibility. Additionally, 
increased risks of childhood ALL was associated with increased 
dust levels of herbicide combustion sources and organochlorine 
compounds. 
Sergio Koifman presented a hospital-based case-control study 
in which the participants were enrolled between 1999 and 2006 
with ALL, AML and a control group. Moderate increased risk for 
acute leukaemia was associated with a birth weight of 3500 gm 
or more (OR 1.88 95% CI 1.29–2.15). Increased ORs were 
observed comparatively to quartile of birthweight distribution: 
OR = 1.46 95% CI 0.79–2.71 in the second quartile OR = 3.18 
95% CI 1.83–5.53 in the third quartile and OR = 3.57 95% CI 
2.07–6.18 in the fourth quartile. Similar trends were observed 
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according to birthweight strata for ALL and AML. Some 
hypotheses for the biological mechanisms relating birthweight to 
the development of infant acute leukaemia (IAL) were proposed. 
One of them being hormonal intake during pregnancy, which in 
a previous analysis showed a high association with IAL with an 
OR 8.76 95% CI 2.85–26.93 (Pombo-de-Oliveira MS 2006). 
Cellular and immunomolecular profiling of childhood leukaemia 
in Brazil was described by Maria S Pombo-de-Oliveira as a 
consequence of the Brazilian immunomolecular study group. 
The results according to immunophenotyping and genotyping 
profiles demonstrated the same frequencies of biomarkers as 
described worldwide. There was a positive change in the 
process of identification of childhood leukaemia and an 
improvement in diagnosis. The amount of biological samples 
sent for diagnosis increased threefold in 2000–07 (n=3618) 
compared to 1990–9 (n=1003). Increasing expectations of these 
improvements was hampered by the complexity of the overlap 
from local infectious diseases. Differential diagnosis of local 
parasitic disease is under evaluation. Kala-zar, an infectious 
disease caused by Leishmania chagasi, an important medical 
problem mainly in the Northeast and Central plateau regions 
(1310–7616 cases reported annually), is either treated with 
glucantine or amphotericin B. A particular topic under 
exploration is whether Kala-zar, or its treatment could represent 
the second hit for the development of childhood c-ALL. A 
proposal to start an exploratory epidemiological study combined 
with genomic signature was positively accepted. Other 
questions were raised, such as previous exposure to 
medications leading to bone marrow abnormalities and the 
standardisation of protocols to identify minimal residual disease 
in ALL.  
An international collaboration, supported by the International 
Agency on Research for Cancer (IARC), was described by 
Catherine Metayer and Beatriz de Camargo (INCA, Brazil). 
Catherine Metayer reviewed the history of Childhood 
Leukaemia International Consortium (CLIC), established in 
collaboration with UC Berkeley and IARC to overcome the 
limitations of childhood leukaemia studies, due to limited 
number of samples especially for rare subtypes. The objective 
is to combine existing data from several comparable case-
control studies conducted in Northern Europe, Southern 
America and Asia to increase the numbers to approximately 
8000 childhood leukaemia and 13,000 controls. Because of the 
participation from New Zealand, Seoul, Australia, United 
Kingdom, Quebec, Montreal, Italy, France, Germany, Brazil and 
California (USA), 8106 cases and 13,303 controls have been 
collected since 1989. Fifty per cent of these have DNA 
specimens available. 
Following on, Beatriz de Camargo presented the new proposal 
from the IARC on an International Study of non-CNS Embryonal 
Tumours (ISET). The rational for this proposal is the lack of 
large-scale aetiological studies on solid embryonal tumours. 
The study will be started with a pilot project on WTs and 
neuroblastoma. The objective of the full scale study is to 
understand the aetiology of embryonal tumours, focusing on 
genetic susceptibility prenatal factors and neonatal exposures 
as well as aspects of molecular epidemiology, including 
epigenetic profiles, DNA repair capacity and mutation patterns. 
Dual role for NFAT transcription factors in regulation of 
apoptosis cell proliferation and transformation of T and B cells 
was presented by João Viola (CPq-INCA). The functional role of 
NFAT1 and 2, demonstrated in knockout mice for the first time, 
indicated a dichotomous role of NFAT family members in cell 
cycle control. This should be evaluated in human models as 
NFAT1 suppresses cell transformation of the neoplastic cells 
may act as a tumour suppressor. 
Genetic polymorphisms and susceptibility to childhood acute 
lymphoblastic leukaemia was discussed by Carlos Scrideli 
(Faculdade de Medicina de Ribeirão, Preto, São Paulo). 
CYP2D6, CYP3A5, EPHX1, MPO, NQO1, NAT2, TS, XRCC1 
and  XPD polymorphisms were studied in a group of children 
with acute lymphoblastic leukaemia and CYP2D6 (del A and 
G/A), CYP3A5 (*3) and XPD (A/C) may have an important role 
in increasing the risk of ALL in children. EPHX1 (T/C and A/G), 
TS (tandem repeat), NQO1 (C/T) and MPO (G/A) 
polymorphisms may have a role in protection against ALL. 
Juliana Godoy Assumpção discussed a study on the role of 
TP53 R337H mutation in paediatric ALL, which was tested in a 
group of 208 children treated at the Centro de Investigações 
Infantil D Boldrini Campinas, São Paulo, during the period 
2001–07. Although this alteration is already known to be 
associated with adrenocortical tumours in Brazilian children, no 
association of the TP53 R337H mutation was found in ALL. 
A large review of the literature in case-control studies in AML 
was carried out by Maria Lucia de Martino Lee (Instituto de 
Oncologia Pediatrica/UNIFESP São Paulo). Risk factors such 
as alcohol during pregnancy, parental exposures to pesticides 
and drugs exposure were mentioned. Comparison of the 
incidence of chromosomal abnormalities in different regions of 
the world was also reviewed. The proportion of promyelocytic 
leukaemia in Hispanic children varies with the series of cases 
considered, ranging from 13.0% to 37.5%.  The same can be 
observed in the Brazilian series of AML cases. A proposal for a 
new multi-institutional study of chromosomal abnormalities in 
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AML was disclosed by Maria Luiza Macedo Silva (CEMO-
INCA). 
The integration of flow cytometry into AML protocols, to assess 
levels of minimal residual disease, was presented by Mihoko 
Yamamoto (UNIFESP São Paulo). The detection and clinical 
significance of aberrant phenotypes associated with molecular 
detection of fusion gene was reviewed. The mutation analysis of 
FLT3 in AML was presented by Ilana Zalcberg (CEMO-INCA). 
This study used an innovative approach that searches for 
unidentified activating FLT3 mutations and NPM1 abnormalities. 
 
Embryonal tumours 
Childhood cancers originate from embryonal cells during 
prenatal and post-natal development. Defects in any of the 
pathways that control development, tissue growth and 
differentiation can promote transformation, making these cells 
particularly prone to carcinogenesis. These pathways were 
elegantly discussed by Rogier Versteeg (Academic Medical 
Centre, The Netherlands) specifically in neuroblastoma. 
Embryonal tumours have clinical and epidemiological common 
features that suggest common pathways. Features such as age 
of onset, birthweight and association with congenital 
abnormalities were reviewed by Beatriz de Camargo. It is well 
known that children with cancer have a high incidence of 
malformation syndromes. WT has been reported in association 
with more than 50 different clinical conditions and several 
abnormal constitutional karyotypes. High-risk syndromes 
(>20%) associated with WT include Denys-Drash syndrome, 
Perlman syndrome, Familial WT and WAGR syndrome. 
Beckwith-Wiedman syndrome and Simpson-Golabai-Behmel 
syndrome are associated with a moderate risk of 5–20%. 
Isolated hemi-hypertrophy and several other syndromes have 
been described in association with WT. High birthweight has 
been identified as a possible risk factor for WT in several 
population-based studies, but results are not consistent outside 
the context of overgrowth disorder association. Low birthweight 
is associated with hepatoblastoma in several reports. For 
rhabdomyosarcoma, the histological alveolar subtype is 
associated with heavier birthweight, suggesting that this should 
be analysed separately. Costello syndrome and type 1 
neurofibromatosis is associated with embryonal 
rhabdomyosarcoma. All embryonal tumours are associated with 
Beckwith-Wiedman and some other overgrowth syndromes. 
Birthweight and congenital anomalies suggest that there are 
critical time points during the gestation and common risk 
factors. 
An overview of the recommendations for genetic counselling in 
children with embryonic tumours was presented by Fernando 
Vargas (INCA-Brazil). Although the percentage of childhood 
cancers with a clearly inherited predisposition is low, sentinel 
karyotyping should be beneficial in children with a genetic 
abnormality.  Structural chromosomal aberrations such as del 
(1p36), del (8q24.1), del (9p24), del (11p13) and del (13q14) 
are strongly associated with neuroblastoma, osteosarcoma, 
gonadoblastomam WT and retinoblastoma. The criteria for 
genetic testing and genetic counselling were presented. 
Down’s syndrome (DS) offers a natural genetic model for 
cancer protection. A review of the association of DS with 
paediatric neoplasm was presented by Isis Magalhães (Hospital 
de Base Brasilia).  A study of 17,897 Americans with DS 
confirmed the higher incidence of leukaemia and testicular 
cancer and a lower incidence of breast cancer. A study of 3581 
persons with DS in Finland has also reported a higher risk of 
leukaemia and testicular cancer, and a lower risk for solid 
tumours than in the general population. Aneuploidy  of 
chromosome 21 has been linked to leukemogenesis, as trisomy 
or tetrasomy of chromosome 21 is common in childhood ALL. In 
recent years, it has been reported that somatic mutations in the 
X-linked GATA1 gene are present in AML blasts of DS children. 
In order to test whether specificity of GATA1 mutations would 
be a helpful tool to distinguish different haematopoietic 
disorders in children with DS, samples from a cohort of DS 
children were analysed. GATA1 mutations in haematological 
clonal disorders were found in 75% of AMLs. Although inherent 
mutation leading to the production of the short isoform of 
GATA1 is associated with impaired megakaryopoiesis and 
erythropoises, it does not lead to leukaemia in the absence of 
trisomy 21. Therefore, trisomy is essential for the 
leukemogenesis with additional changes characterized by a 
third hit. 
The correlation between histology and molecular features was 
reviewed by Paulo Faria (INCA-Brazil). Chromosomal 
abnormalities including reciprocal translocations, deletions, 
mutations and amplifications have a specific histopathology 
type. WT1 mutations are associated with intralobar nephrogenic 
rests and rhabdomyomatous differentiation. Gene fusions such 
as PAX3-FKHR and PAX-7-FKHR are associated with alveolar 
rhabdomyosarcoma, while other abnormalities are present in 
embryonal rhabdomyosarcomas. The Ewing’s sarcoma family of 
tumours has several histology features, but all share a common 
molecular pathogenesis (chromosomal translocations of EWS 
gene and one of the several members of ETS family of 
transcription factors). Recognition of morphological and 
molecular features is important for determining biological 
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behaviour. Classifications of paediatric neoplasms should 
include morphology immunohistochemical and molecular 
biologic aspects. The importance of the cancer biobanking was 
highlighted. 
As embryonal tumours differ from adult tumours, it is important 
to study them under the perspective of organ development, 
taking into consideration histological differentiation. WT 
morphology is similar to specific development phases of kidney 
morphogenesis. 
In a study, Dirce Carraro (Hospital AC Camargo, São Paulo) 
demonstrated that the blastema component preferentially 
presented gene expression patterns similar to the earliest stage 
of kidney development, suggesting that morphological aspects 
acquired by WT are dependent on the temporal and spatial 
occurrence of the mutation in embryonic blastema during kidney 
development.  
The evolving story of WT biology was reviewed by Jeff Dome 
(Children’s National Medical Center, Washington, DC, USA). 
WT, whose pathogenesis was once thought to follow the same 
single-gene, two-hit model as retinoblastoma, has instead 
become a paradigm for genetic heterogeneity and complexity. 
Several genes have been implicated in its development, most of 
which are associated with familial disease or malformation 
syndromes that affect only a small fraction of cases. 
Constitutional deletions of WT1 at 11p13 is well established as 
the genetic basis for WAGR (WT aniridia genitourinary anomaly 
mental retardation), while germ line mis-sense mutations in 
WT1 are responsible for WT occurring as part of Denys-Drash 
syndrome. Several candidate genes at the second WT locus 
WT2 have been described. WT1 is altered in only approximately 
20% of WT.  Beta-catenin mutations have been described as 
present in 15%, and Wnt signalling pathway is probably 
implicated in this neoplasm. Recently, a novel gene WTX at 
Xq11.1 was reported to be mutated in WT. Genetic 
abnormalities are known in about 75% of tumours: 15% WT; 
30%  WT2; 30% WTX. Much progress has been made in 
understanding the biology of WT. 
An 11-year study carried out in Southern Brazil (Mara 
Pianoviski, Curitiba, Brazil) emphasized that there was a 
significant delay in diagnosis, resulting in less successful 
treatment and poorer survival in children less than two years of 
age. The frequency of amplified N-myc was higher than that 
reported by other studies. In a series of patients from Parana, 
Southern Brazil, all the male patients with amplified N-myc and 
unfavourable histology who died were of an older age and a 
more advanced stage of disease, which suggested late 
diagnosis. 
A study carried out in INCA on the amplification of N-myc in 
tumours was reported by Arissa Ikeda (INCA, Brazil). Twenty-
nine tumour samples, 14 fresh and 21 paraffin embedded were 
analysed. Nine had amplifications and this was correlated with 
the outcome. N-myc evaluation is routinely recommended to all 
patients for risk classification and appropriate treatment 
strategy. However, cost–benefit effectiveness in our country 
was discussed, and this type of evaluation was recommended 
mainly in children with neuroblastoma, with localized disease 
stage INSS 2A/2B/3, stage 4S and INSS stage 4, at less than 
one year old. 
A presentation of treatment strategies was given by Jeff Dome 
for WT and Barbara Hero (University Hospital Cologne 
Germany) for neuroblastoma. There are two major approaches 
in WT, one with pre-chemotherapy and the other with surgery 
first. Both approaches have similar overall survival. Modern 
approaches to WT treatment include both reduction of therapy 
and augmentation of therapy. Reduction strategies are being 
tested by SIOP (Europe and Brazil) and COG (USA), and these 
propose the omission of doxorubicin in stage II/III, omission of 
chemotherapy in stage I small tumours and omission of lung 
irradiation for rapid responders. Augmentation therapies are 
being tested in patients with tumours presenting LOH 1p/16q, 
patients with tumours histology after chemotherapy blastema-
predominant stage IV, patients with anaplasia. New agents are 
becoming available; the most promising are the microtubule 
inhibitors ixabepilone and ABT-751. An international relapse 
protocol will be started with ICE (ifosfamide carboplatin 
vincristine)-topotecan as an induction phase, followed by 
randomization to BMT (autologous bone marrow transplant) or 
maintenance. The treatment approach for neuroblastoma goes 
from minimal intervention in stages 1, 2, 4S and stage 3 less 
than two years, to maximal treatment in stage 4 patients over 
one year old and tumours with n-MYC amplification. A wait-and-
see strategy in localized disease and children less than one 
year old is recommended. Induction surgery, megatherapy, 
radiotherapy and consolidation therapy are given to high-risk 
patients. In conclusion, risk adapted treatment is necessary for 
children with neuroblastoma. Data from an experience with a 
dendritic-cell tumour, in which cell hybrid vaccination was given 
every six weeks in advanced relapse neuroblastoma (Alexandre 
Barbuto, ICB USP São Paulo, Brazil) indicated that immune 
function, recovery and time to tumours progression was 
delayed. 
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Prognostic risk classifications in ALL Wilms' 
tumour and neuroblastoma 
The survival rate of childhood cancer has exceeded 80% and 
classification of prognostic risk is essential for treatment 
strategies. Current prognostic factors for WT neuroblastoma 
and acute lymphoblastic leukaemia were reviewed by Jeff 
Dome, Barbara Hero, Silvia R Brandalise, (Centro de 
Investigações Infantil D Boldrini Campinas, São Paulo) and 
Marco Borato Vianna (Universidade Federal de Minas Gerais, 
Brazil), respectively. 
In WT, the most important negative prognostic factor is 
histological findings of anaplasia. Recent research has focused 
on identification of possible molecular genetic markers. In the 
study of NWTS-3–4, loss of heterozygosity for markers on 
chromosome 16q and 1p was associated with poorer two-year 
relapse-free and overall survival rates. This observation was 
tested on NWTS-5 and confirmed in tumours with loss of 
heterozygosity jointly for both chromosomes 1p and 16q. The 
level of telomerase expression in tumours has been correlated 
with risk of tumour recurrence. Gain of chromosome 1q is 
associated with loss of 1p and 16q and is under evaluation as a 
risk factor. Gene expression arrays were of limited value until 
now. Tumours are heterogeneous with regard to their relapse 
signatures. 
The major prognostic variables in neuroblastoma are age at 
diagnosis stage, N-myc amplification status, tumours cell 
ploidy, 1p deletions and tumours pathology. The most important 
independent factor is still N-myc amplification. 
Prognostic values in ALL are age, white blood count at 
diagnosis, early response to treatment, cytogenetics, 
immunophenotyping, molecular biology and in vitro drug 
sensitivity. This knowledge is useful for stratifying patients into 
low, moderate and high-risk groups. 
The Brazilian Cooperative Study Groups (GBTLI) were 
reviewed by Silvia R Brandalise. The GBTLI-93 stratified 
children with ALL into three groups: very low risk (age between 
>=1 and <= 10 years, white blood count at diagnosis 
<=10000/mm, no mediastinal mass without CNS involvement), 
low risk (age between >=1 and <= 10 years, white blood count 
at diagnosis between 10.000/mm and < 50000/mm with or 
without mediastinal mass) and high risk (ageə year or >=10 
years, white blood count at diagnosis >=50000 with or without
CNS involvement). Overall survival was 84%, 81% and 57%, 
respectively. In a following study, GBTLI-99 patients were 
classified as high risk (age ə year or > 9 years white blood count 
< 50000) and low risk (age between one and 10 years white 
blood count < 50000). Although immunomolecular results were 
not considered for risk definition, immuno-phenotyping, DNA 
index and molecular biology were performed in 92%, 64% and 
51% of the cases, respectively. Event-free survival was 59% for 
high-risk and 78% for low-risk patients. Socio-economic factors 
were discussed by Marco Borato Vianna. Overall survival for 
children with ALL living in underdeveloped or developing 
countries is clearly inferior to those in developed countries. 
Environmental factors such as nutritional status, total income of 
the family, height for age and ethnicity have been published as 
prognostic factors. Compliance, treatment, intensity and genetic 
polymorphisms are also important in predicting 
outcome.  Additional efforts should be undertaken to clarify 
mechanisms of socioeconomic influence that are clearly 
multifactorial. 
The visibility of the Brazilian network, so-called Rede de 
Atenção Oncológica, has been improving the research and 
outcome in paediatric oncology (presented by Marco Porto, 
INCA, Brazil). The aim of this enterprise is mainly to reduce 
mortality and improve quality of life of cancer patients in Brazil. 
There is a strong commitment and participation from 
government and non-government organisations. The 
epidemiological and immunomolecular study (sponsored by 
INCA FAF/Swiss Bridge Foundation) is currently working very 
well. Cases are notified, samples are sent by courier overnight 
to be analysed and their results promptly available online. The 
establishment of this network represents a potential contribution 
to assist the demands of clinicians and researchers. 
 
Conclusions 
Discussion was stimulated by the organizing committee (Maria 
S Pombo-de-Oliveira, Sima Ferman and Beatriz de Camargo) 
with colleagues from all over Brazil having the opportunity to 
exchange experiences. The meeting provided an outstanding 
overview on molecular epidemiology in paediatric leukaemia 
and embryonal tumours. International scientific collaboration 
provided direction for future research, which has been, or will 
be, implemented. 
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